DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,034 filers reported holding DANAHER CORPORATION in Q1 2023. The put-call ratio across all filers is 0.99 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $358,786 | +7.5% | 1,446,134 | +4.0% | 0.52% | +20.8% |
| Q2 2023 | $333,761 | -1.9% | 1,390,670 | +3.0% | 0.43% | -6.4% |
| Q1 2023 | $340,189 | -2.7% | 1,349,743 | +2.5% | 0.46% | -4.8% |
| Q4 2022 | $349,667 | -99.9% | 1,317,411 | +0.6% | 0.48% | -2.2% |
| Q3 2022 | $338,277,000 | -1.2% | 1,309,680 | -3.0% | 0.49% | +9.6% |
| Q2 2022 | $342,384,000 | -10.5% | 1,350,520 | +3.6% | 0.45% | +9.3% |
| Q1 2022 | $382,386,000 | -13.8% | 1,303,602 | -3.3% | 0.41% | -8.1% |
| Q4 2021 | $443,468,000 | +6.6% | 1,347,887 | -1.4% | 0.44% | +0.5% |
| Q3 2021 | $415,994,000 | +2.3% | 1,366,424 | -9.8% | 0.44% | +5.2% |
| Q2 2021 | $406,573,000 | +11.7% | 1,515,027 | -6.3% | 0.42% | +4.7% |
| Q1 2021 | $363,829,000 | -1.7% | 1,616,442 | -3.0% | 0.40% | -2.7% |
| Q4 2020 | $370,213,000 | -1.4% | 1,666,576 | -4.5% | 0.41% | -10.0% |
| Q3 2020 | $375,604,000 | +15.6% | 1,744,320 | -5.1% | 0.46% | +10.9% |
| Q2 2020 | $324,941,000 | +27.3% | 1,837,587 | -0.4% | 0.41% | +7.8% |
| Q1 2020 | $255,355,000 | -9.6% | 1,844,918 | +0.2% | 0.38% | +14.3% |
| Q4 2019 | $282,581,000 | +4.2% | 1,841,157 | -1.9% | 0.34% | -2.0% |
| Q3 2019 | $271,095,000 | -0.1% | 1,877,002 | -1.1% | 0.34% | +0.9% |
| Q2 2019 | $271,362,000 | +16.1% | 1,898,702 | +7.3% | 0.34% | +13.3% |
| Q1 2019 | $233,692,000 | +36.7% | 1,770,122 | +6.8% | 0.30% | +21.0% |
| Q4 2018 | $170,939,000 | -9.5% | 1,657,670 | -4.6% | 0.25% | +10.7% |
| Q3 2018 | $188,793,000 | +7.9% | 1,737,470 | -2.0% | 0.22% | +2.8% |
| Q2 2018 | $174,981,000 | -1.7% | 1,773,220 | -2.5% | 0.22% | -1.4% |
| Q1 2018 | $178,090,000 | +3.7% | 1,818,920 | -1.7% | 0.22% | +6.8% |
| Q4 2017 | $171,802,000 | +8.7% | 1,850,920 | +0.5% | 0.21% | +2.5% |
| Q3 2017 | $158,007,000 | +3.0% | 1,842,000 | +1.3% | 0.20% | 0.0% |
| Q2 2017 | $153,413,000 | -8.2% | 1,817,900 | -7.0% | 0.20% | -10.2% |
| Q1 2017 | $167,117,000 | +10.3% | 1,953,897 | +0.4% | 0.22% | +5.1% |
| Q4 2016 | $151,531,000 | -3.6% | 1,946,696 | -2.9% | 0.21% | -5.3% |
| Q3 2016 | $157,160,000 | -24.1% | 2,004,846 | -2.1% | 0.23% | -25.2% |
| Q2 2016 | $206,928,000 | +9.2% | 2,048,794 | +2.5% | 0.30% | +4.1% |
| Q1 2016 | $189,526,000 | +4.3% | 1,997,958 | +2.1% | 0.29% | +3.9% |
| Q4 2015 | $181,669,000 | +1.9% | 1,955,958 | -6.5% | 0.28% | -1.1% |
| Q3 2015 | $178,215,000 | +1.2% | 2,091,484 | +1.7% | 0.28% | +9.7% |
| Q2 2015 | $176,074,000 | +0.1% | 2,057,176 | -0.7% | 0.26% | 0.0% |
| Q1 2015 | $175,816,000 | -7.0% | 2,070,857 | -6.1% | 0.26% | -8.2% |
| Q4 2014 | $189,058,000 | +13.6% | 2,205,783 | +0.7% | 0.28% | +12.4% |
| Q3 2014 | $166,485,000 | +7.8% | 2,191,167 | +11.7% | 0.25% | +9.2% |
| Q2 2014 | $154,488,000 | +5.1% | 1,962,255 | +0.1% | 0.23% | +0.4% |
| Q1 2014 | $146,996,000 | -5.9% | 1,959,947 | -3.2% | 0.23% | -7.3% |
| Q4 2013 | $156,246,000 | +9.9% | 2,023,912 | -1.3% | 0.24% | +2.5% |
| Q3 2013 | $142,141,000 | -0.7% | 2,050,512 | -9.3% | 0.24% | -4.8% |
| Q2 2013 | $143,171,000 | – | 2,261,793 | – | 0.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |